Table 7 maspin expression in gastric, pancreatic and gallbladder cancer
From: Role of maspin in cancer
| Authors | Years | N. patients | Maspin expression | Clinical features/prognosis/predictive factors |
|---|---|---|---|---|
| Wang et al. | 2004 | 113 (gastric cancer) | 50.5% positive maspin | Positive maspin = T4: 35.9%, metastasis: 34.3%, subtype diffuse: 42.1%, undifferentiated: 40% |
| 49.5% negative maspin | Negative maspin = T4: 64.1%, metastasis: 65.7%, subtype diffuse: 57.9%, undifferentiated: 60% | |||
| Lee et al. | 2008 | 152 (gastric cancer) | 71.7% positive maspin | |
| 29.3% negative maspin | Negative maspin = undifferentiated, high stage, metastasis and invasion depth, positive p53 | |||
| Liu et al. | 2012 | 102 (pancreatic cancer) | 98% positive maspin | |
| Maas et al. | 2001 | 24 (pancreatic cancer) | 96% positive maspin | |
| 5 (PanIn3) | ||||
| 100% positive maspin | ||||
| Maesawa | 2006 | 69 (cholelithiasis) | 14% positive maspin | |
| 14 (cholelitiasis + intestinal metaplasia) | ||||
| 64%positive maspin | ||||
| Kim et al. | 2012 | 101 (gallbladder cancer) | 59.4% positive maspin | |
| 25(adenoma) | 100% negative maspin | |||
| 10 (normal gallbladder) | ||||
| 100%negative maspin |